Newly Confident Hutchmed Weans Itself from Partners, Prepares to Stand on Its Own
Oncological drug specialist backed by billionaire Li Ka-shing sells OTC business and raises $200 million, half from Baring Private Equity Asia Key Takeaways Hutchmed predicts revenue from its core oncology…
RELATED ARTICLES
-
NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
0013.HK HCM.US -
Earnings blow for CSPC Pharma as the state drives a hard bargain
1093.HK
- Cancer drug maker Genfleet joins Hong Kong IPO influx
-
Everest Medicines drives growth with AI-powered mRNA pipeline
1952.HK
-
A blockbuster cancer drug? TYK’s claims go under the microscope
2410.HK
-
Xuanzhu Biopharm set for spin-off in Hong Kong IPO
0460.HK
